Revvity. has been granted a patent for compositions and methods involving anti-TSPAN33 agents, including monoclonal antibodies and their derivatives. The patent details the structural requirements for these agents, specifically the immunoglobulin heavy and light chain variable domains and their complementarity determining regions. GlobalData’s report on Revvity gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Revvity, Laboratory automation robots was a key innovation area identified from patents. Revvity's grant share as of June 2024 was 57%. Grant share is based on the ratio of number of grants to total number of patents.
Anti-tspan33 agents, including monoclonal antibodies and fragments
The granted patent US12006363B2 outlines a novel anti-TSPAN33 agent designed to bind specifically to Tetraspanin 33 (TSPAN33) under both laboratory and physiological conditions. This agent is characterized by its composition, which includes at least one immunoglobulin heavy chain variable domain and one immunoglobulin light chain variable domain. Each of these domains contains complementarity determining regions (CDRs) that are crucial for the binding specificity. The claims detail the structural requirements for these domains, including specific amino acid sequences that must exhibit a high degree of identity to predefined sequences. Additionally, the anti-TSPAN33 agent may be conjugated to a detectable marker or immobilized on a solid support, enhancing its utility in various applications.
The patent further encompasses isolated nucleic acid molecules that encode the variable domains of the anti-TSPAN33 agent, as well as recombinant expression vectors designed to produce these domains. A significant application of the anti-TSPAN33 agent is in the detection of TSPAN33 in biological samples, where it can form complexes that can be identified. Furthermore, the claims include methods for treating or preventing diseases associated with abnormal TSPAN33 levels by administering the anti-TSPAN33 agent to affected individuals. This multifaceted approach highlights the potential of the anti-TSPAN33 agent in both diagnostic and therapeutic contexts, addressing conditions linked to TSPAN33 dysregulation.
To know more about GlobalData’s detailed insights on Revvity, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
